Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
about
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerSystems biology of cisplatin resistance: past, present and futureDietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cellsVorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cellsThe therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancerThe effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilizationThe effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cellsThe DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cellsVorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancerExpression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.NFκB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC).Beyond triple-negative breast cancer: the need to define new subtypes.Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.Basal phenotype breast cancer: implications for treatment and prognosis.Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors.Addressing intra-tumoral heterogeneity and therapy resistance.HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combinationBRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.Targeting the ERK signaling pathway as a potential treatment for insulin resistance and type 2 diabetes.Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells.Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney.An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy.
P2860
Q26777453-52DF99F7-37D9-4325-BC41-5BCACC6B2EA7Q26863585-68AB5E4E-055E-4471-B743-F20C21CE353CQ28257534-88DB08AC-582D-4822-B1EB-290291694FB9Q28743758-0AEF63BA-F590-48C7-9E37-3C9A8E37DEA1Q33659166-97F3D956-06CF-4E5B-8B3F-D40BDF039E46Q34351080-C99AB6D7-8CB6-4631-86DD-AEAAD48E31C7Q34618963-9EA73E6C-F4B0-4442-908B-9ED2E8A0B20AQ35059923-DD820EFF-AF08-4E5E-ACD5-D008171E203FQ35218534-E98893A3-3D6F-4948-9E64-14C8E6962764Q35556954-C3139A88-F547-4832-BA23-4EC3DBD49CEFQ36184617-011A7A9D-13F6-4E55-B6CC-44CD29394E9AQ36521908-D0564E36-588D-47D7-940A-08D1FC6689AEQ36537920-137ABF41-7200-45D0-B13A-B450B9FE5F7FQ36840303-D2ECAF4F-E343-48FE-A9E6-8291C2A5C35DQ37200466-C8B529DE-E463-4F56-811B-0C1DD4DADBAAQ37290559-358B9A15-29DB-4932-BABF-544CD5C87796Q37455875-2519E0E2-25DB-4845-A7BB-9A421332F15DQ37534990-A2426A0E-A86F-4788-B5D6-136F206CBCFAQ37782088-98FC14D3-D0ED-473A-9CD3-D602A5FFBF2CQ37813392-5AC80B83-9EEA-483D-9BA1-64A32C1AC4D4Q37853555-647C433B-32FA-44C3-B5BB-52216AC5EFBEQ38543089-10E89881-A517-4CF9-89CF-9C77F04586B0Q38823179-F8B21408-0429-4640-B539-EFD67E953D4BQ39706886-76E1E967-3B52-4DB8-93B2-B237709AAF44Q39718655-D769300A-D5DB-4180-84BD-EC2708F09236Q41972847-66B84182-7CAC-46DA-B093-9716E9B05FB9Q42061759-F941EB2E-63B8-4D86-BCAC-B0F34AB8961CQ42814401-8E7DD168-083C-4DC8-951B-2200AC8D5E3EQ48119543-A78B7542-22A9-4D1E-8AAE-4A9A25FF8244Q52739228-94F58852-0FA3-4875-BE8F-0AFE5001B972Q53260628-6B91B915-F10C-4FEC-840D-DBBDC6914922Q55106924-28076F3D-D71D-4A28-A279-EA77FB1C8BBD
P2860
Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Histone deacetylase inhibitors ...... e range of DNA-damaging drugs.
@en
type
label
Histone deacetylase inhibitors ...... e range of DNA-damaging drugs.
@en
prefLabel
Histone deacetylase inhibitors ...... e range of DNA-damaging drugs.
@en
P2093
P2860
P1433
P1476
Histone deacetylase inhibitors ...... e range of DNA-damaging drugs.
@en
P2093
Futaba Kishikawa
Kei-ichi Ozaki
Masashi Tanaka
Michiaki Kohno
Susumu Tanimura
Toshiaki Sakamoto
P2860
P304
P356
10.1111/J.1349-7006.2007.00669.X
P577
2008-01-15T00:00:00Z